Wound Center of Niagara selected for groundbreaking clinical study

dr

Share with:

FacebookTwitterGoogleTumblrLinkedInRedditPinterestEmail this pagePrint this page


Collaborates with Nuo Therapeutics Inc. on Aurix™ System study

The Wound Center of Niagara at Niagara Falls Memorial Medical Center has been selected with RestorixHealth and Nuo Therapeutics to participate in a nationwide clinical study of a breakthrough therapy for treating chronic, non-healing wounds.

The study begins this month at The Wound Center of Niagara and will evaluate the overall effectiveness of a new technology called Aurix™. The Centers for Medicare and Medicaid Services (CMS) recently decided to investigate the effectiveness of Aurix Therapy by supporting and reimbursing a real world clinical study involving Medicare patients and focused on collecting wound healing data in a registry format.  The Wound Center of Niagara is one of a select number of centers in the U.S. conducting randomized, controlled testing under this important Medicare program.

“We are excited to have been selected to take part in this pragmatic approach to studying the potential benefits to Medicare beneficiaries of a promising treatment option,” said Michael Mitchell, M.D., the Wound Center of Niagara’s medical director. “Clinical results have shown Aurix Therapy to be safe and effective and we are pleased to be able to offer it to qualifying Medicare patients here in Niagara.”

dr
Dr. Michael Mitchell

Aurix™ is a biodynamic hematogel product approved by the Food and Drug Administration for wound management and is derived from the patient’s own blood platelets and plasma. Once topically applied, it stimulates the formation of new tissue to fill in wound defects and reduce wound volume.

The current study will involve treating patients who have diabetic, venous or pressure ulcers in three separate protocols and will help CMS understand the benefit of Aurix Therapy to Medicare patients as it is used within the continuum of care and ultimately inform their final long term reimbursement determination.

This collection of wound healing data under CMS’ Coverage with Evidence Development program is oriented towards an ‘evidence based medicine’ approach where treatment will be assessed in the context of real world clinical situations and comorbidities.  The potential cost savings to the overall health system can be substantial if non-healing chronic wounds can be placed on a rapid healing trajectory.  Clinicians within the wound healing community realize that a variety of products and approaches may be both necessary and appropriate as a chronic wound progresses to complete healing.

The Wound Center of Niagara in November was named a second-time recipient of RestorixHealth’s Center of Excellence Award. The award distinguishes centers that have demonstrated exceptional success by meeting or exceeding clinical, operational and financial benchmarks including healing outcomes and safety, along with a patient satisfaction rate of 95 percent or higher.

Comprehensive wound care at The Wound Center of Niagara is provided by a multidisciplinary team of physicians who have received specialized training in complex wound management as well as expert nursing staff.  The center is part of a national network of wound clinics that track their success rate and continuous quality improvement through the U.S. Wound Registry.

 

About Niagara Falls Memorial Medical Center

Niagara Falls Memorial Medical Center is a 171-bed regional hospital system serving patients from Western New York, Southern Ontario and beyond.  Its inpatient services include cardiac, stroke, medical-surgical and behavioral health care.  Satellite sites, including six primary care physician offices and the new Golisano Center for Community Health, provide a full range of medical, diagnostic and mental health services. For more information, visit NFMMC.org.

About Nuo Therapeutics, Inc.

Nuo Therapeutics is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape. AurixTM is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the wound healing process.  To learn more visithttp://www.nuot.com.  To learn more about the study, call 1-866-298-6633.

About RestorixHealth

RestorixHealth, a leading wound care management company, develops and manages centers of excellence for amputation prevention, wound management and hyperbaric medicine. Forging strong relationships with their partners, RestorixHealth provides high quality, cost-efficient solutions to wound care that offer advanced treatment therapies along with hyperbaric oxygen therapy. Founded by physicians in 1997 to treat the growing incidence of chronic, non-healing wounds, RestorixHealth’s centers utilize a quality- and data-driven approach to consistently achieve high treatment success rates, resulting in a dramatic improvement in patient quality of life. The company manages comprehensive centers throughout the United States in partnership with hospitals and health care facilities. For more information, visit www.restorixhealth.com.

 

Share with:

FacebookTwitterGoogleTumblrLinkedInRedditPinterestEmail this pagePrint this page


Leave a Reply

Your email address will not be published. Required fields are marked *